--- title: "Bayer AG Stock 12‑Month Price Target Raised to €56.03, Implies 19% Upside" type: "News" locale: "en" url: "https://longbridge.com/en/news/294860516.md" description: "Bayer AG's average 12-month price target has been raised to €56.03 by 18 analysts, up from €55.03, implying a 19% upside based on the August 3 closing price. The consensus rating remains 'Buy' among 21 covering analysts, with forecasts ranging from €46 to €65 per share." datetime: "2026-08-04T19:20:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294860516.md) - [en](https://longbridge.com/en/news/294860516.md) - [zh-HK](https://longbridge.com/zh-HK/news/294860516.md) generator: "portal-rs" --- # Bayer AG Stock 12‑Month Price Target Raised to €56.03, Implies 19% Upside - According to estimates from 18 analysts, Bayer AG stock's average price target has risen from €55.03 to €56.03, with forecasts ranging from €46 to €65 per share - Based on the Aug. 3 closing price, the updated target implies approximately 19% potential upside - Consensus rating remains at “Buy” across 21 covering analysts, with 15 Buys, 5 Holds and 1 Sells Explore more price target data and ratings for Bayer AG on the , and track all previous and future analyst recommendations for Bayer AG in the dedicated News Flow. **Disclaimer** Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice. ### Related Stocks - [BAYRY.US](https://longbridge.com/en/quote/BAYRY.US.md) - [BAYN.DE](https://longbridge.com/en/quote/BAYN.DE.md) - [BAYZF.US](https://longbridge.com/en/quote/BAYZF.US.md) ## Related News & Research - [Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Increases By 94.9%](https://longbridge.com/en/news/296026963.md) - [Bayer says Japan approves sevabertinib for HER2-mutant NSCLC](https://longbridge.com/en/news/296745277.md) - [MustGrow Receives First Milestone Payment from Bayer AG | MGROF Stock News](https://longbridge.com/en/news/296609006.md) - [BAYN: Strong 2025 results, innovation focus, and €2bn cost savings drive improved financial outlook](https://longbridge.com/en/news/294831947.md) - [Bayer Swings to Net Profit on Smaller Litigation Charges](https://longbridge.com/en/news/294778020.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**